Symbiox Investment & Trading net profit rises 15.5% in Q1FY27
Symbiox Investment & Trading Co Ltd posted a 15.5% YoY rise in net profit to ₹7.73 lakh for Q1FY27, driven by a 59.2% drop in total expenses that offset a 44.3% decline in revenue. The board approved the results on August 12, 2026, with statutory auditors SSRV & Associates issuing an unqualified review report.
*this image is generated using AI for illustrative purposes only.
Symbiox Investment & Trading Co Ltd reported a net profit of ₹7.73 lakh for the quarter ended June 30, 2026, marking a 15.5% year-on-year increase from ₹6.69 lakh in Q1FY26. This profit growth occurred despite a significant 44.3% decline in revenue from operations, which dropped to ₹25.53 lakh from ₹45.81 lakh in the prior year period. The divergence between falling revenue and rising profitability highlights a shift in the company's cost structure and operational efficiency during the quarter.
The Board of Directors approved the unaudited financial results on August 12, 2026, at its second meeting for the fiscal year 2026-27. The meeting, held at the company’s registered office in Kolkata, also adopted the limited review report issued by the statutory auditor, SSRV & Associates. The results were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance Overview
Revenue from operations declined sharply to ₹25.53 lakh in Q1FY27, compared to ₹45.81 lakh in Q1FY26. This drop was primarily attributed to a reduction in purchases of stock-in-trade, which fell to zero from ₹9.48 lakh in the previous year, and lower changes in inventories, which decreased to nil from ₹13.80 lakh. Total income followed a similar trajectory, standing at ₹25.53 lakh against ₹46.00 lakh in the corresponding quarter of FY26.
| Particulars | Q1FY27 (₹ Lakh) | Q1FY26 (₹ Lakh) | Change (%) |
|---|---|---|---|
| Revenue From Operations | 25.53 | 45.81 | -44.3 |
| Other Income | 0.00 | 0.19 | -100.0 |
| Total Expenses | 15.08 | 36.96 | -59.2 |
| Profit Before Tax | 10.45 | 9.04 | 15.6 |
| Net Profit After Tax | 7.73 | 6.69 | 15.5 |
Total expenses contracted significantly by 59.2% to ₹15.08 lakh, down from ₹36.96 lakh in Q1FY26. Employee benefits expense rose slightly to ₹6.04 lakh from ₹4.07 lakh, while other expenses decreased marginally to ₹8.97 lakh from ₹9.54 lakh. Depreciation remained stable at ₹0.07 lakh. The substantial reduction in total costs outpaced the decline in revenue, contributing to the improved bottom line.
What the Numbers Show
The key analytical observation is the decoupling of revenue and profit trends. While top-line revenue nearly halved due to lower trading activity (evidenced by zero purchases of stock-in-trade), the company managed to increase its net profit. This suggests that the company’s fixed cost base is low relative to its variable costs, or that the mix of remaining revenue was more profitable. The absence of finance costs and minimal depreciation further supports a lean operational model. However, the reliance on inventory changes for revenue recognition in previous periods versus none in the current quarter indicates volatility in trading volumes.
Earnings per share (basic) rose to ₹0.025 from ₹0.021 in the previous year’s first quarter. The paid-up equity share capital remained unchanged at 31,287,330 shares with a face value of ₹10.00 each. The statutory auditor, SSRV & Associates, issued an unqualified review report, confirming that the financial statements present a true and fair view in accordance with applicable accounting standards.
Historical Stock Returns for Symbiox Investment & Trading
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | +0.50% | +25.00% | +16.96% | -28.57% | +28.21% |
Will the company's strategy of minimizing stock-in-trade purchases continue in Q2FY27, or does management plan to resume active trading inventory accumulation?
How sustainable is the current profit margin expansion given the significant 44.3% drop in revenue, and what risks does this lean operational model pose if market conditions shift?
What specific cost-cutting measures drove the 59.2% decline in total expenses, and are these reductions permanent structural changes or temporary adjustments?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
